Japanese drugmaker Shionogi (TYO: 4507) said yesterday that its Xocova (ensitrelvir fumaric acid, Code No.: S-217622), a novel anti-SARS-CoV-2 drug for COVID-19 obtained emergency regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for the indication of SARS-CoV-2 infection, with the news edging the firm’s shares up 2.8% to 7,171 yen.
The company also noted that a contract with the MHLW for the Japanese government to purchase 1 million courses of Xocova is now effective in accordance with the basic agreement for domestic supply of Xocova signed by Shionogi and the MHLW in March 2022.
Shionogi also has a voluntary license agreement for its oral COVID-19 antiviral with the United Nations-backed Medicines Patent Pool (MPP), which aims to increase access to life-saving medicines for low- and middle-income countries (LMICs).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze